APA (7th ed.) Citation

RB, R., K, K., M, F., GD, P., P, R., LC, T., . . . SI, D. (1996). An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: Preliminary evidence for treatment efficacy. Clinical neuropharmacology, 19(4), 341. https://doi.org/10.1097/00002826-199619040-00007

Chicago Style (17th ed.) Citation

RB, Rosse, Kendrick K, Fay-McCarthy M, Prell GD, Rosenberg P, Tsui LC, Wyatt RJ, and Deutsch SI. "An Open-label Study of the Therapeutic Efficacy of High-dose Famotidine Adjuvant Pharmacotherapy in Schizophrenia: Preliminary Evidence for Treatment Efficacy." Clinical Neuropharmacology 19, no. 4 (1996): 341. https://doi.org/10.1097/00002826-199619040-00007.

MLA (9th ed.) Citation

RB, Rosse, et al. "An Open-label Study of the Therapeutic Efficacy of High-dose Famotidine Adjuvant Pharmacotherapy in Schizophrenia: Preliminary Evidence for Treatment Efficacy." Clinical Neuropharmacology, vol. 19, no. 4, 1996, p. 341, https://doi.org/10.1097/00002826-199619040-00007.